These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23672640)

  • 1. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
    Jiang Y; Andrews SW; Condroski KR; Buckman B; Serebryany V; Wenglowsky S; Kennedy AL; Madduru MR; Wang B; Lyon M; Doherty GA; Woodard BT; Lemieux C; Geck Do M; Zhang H; Ballard J; Vigers G; Brandhuber BJ; Stengel P; Josey JA; Beigelman L; Blatt L; Seiwert SD
    J Med Chem; 2014 Mar; 57(5):1753-69. PubMed ID: 23672640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
    Deutsch M; Papatheodoridis GV
    Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
    Scola PM; Wang AX; Good AC; Sun LQ; Combrink KD; Campbell JA; Chen J; Tu Y; Sin N; Venables BL; Sit SY; Chen Y; Cocuzza A; Bilder DM; D'Andrea S; Zheng B; Hewawasam P; Ding M; Thuring J; Li J; Hernandez D; Yu F; Falk P; Zhai G; Sheaffer AK; Chen C; Lee MS; Barry D; Knipe JO; Li W; Han YH; Jenkins S; Gesenberg C; Gao Q; Sinz MW; Santone KS; Zvyaga T; Rajamani R; Klei HE; Colonno RJ; Grasela DM; Hughes E; Chien C; Adams S; Levesque PC; Li D; Zhu J; Meanwell NA; McPhee F
    J Med Chem; 2014 Mar; 57(5):1708-29. PubMed ID: 24555570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
    Duan M; Kazmierski W; Crosby R; Gartland M; Ji J; Tallant M; Wang A; Hamatake R; Wright L; Wu M; Zhang YK; Ding CZ; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2993-6. PubMed ID: 22425454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
    Rosenquist Å; Samuelsson B; Johansson PO; Cummings MD; Lenz O; Raboisson P; Simmen K; Vendeville S; de Kock H; Nilsson M; Horvath A; Kalmeijer R; de la Rosa G; Beumont-Mauviel M
    J Med Chem; 2014 Mar; 57(5):1673-93. PubMed ID: 24446688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.
    Moucari R; Forestier N; Larrey D; Guyader D; Couzigou P; Benhamou Y; Voitot H; Vidaud M; Seiwert S; Bradford B; Zeuzem S; Marcellin P
    Gut; 2010 Dec; 59(12):1694-8. PubMed ID: 20861007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors.
    Chung V; Carroll AR; Gray NM; Parry NR; Thommes PA; Viner KC; D'Souza EA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1381-90. PubMed ID: 15793116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
    Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
    Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
    Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
    Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
    Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
    J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
    Rajagopalan R; Pan L; Schaefer C; Nicholas J; Lim S; Misialek S; Stevens S; Hooi L; Aleskovski N; Ruhrmund D; Kossen K; Huang L; Yap S; Beigelman L; Serebryany V; Liu J; Sastry S; Seiwert S; Buckman B
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
    Miao M; Jing X; De Clercq E; Li G
    Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
    Scola PM; Sun LQ; Wang AX; Chen J; Sin N; Venables BL; Sit SY; Chen Y; Cocuzza A; Bilder DM; D'Andrea SV; Zheng B; Hewawasam P; Tu Y; Friborg J; Falk P; Hernandez D; Levine S; Chen C; Yu F; Sheaffer AK; Zhai G; Barry D; Knipe JO; Han YH; Schartman R; Donoso M; Mosure K; Sinz MW; Zvyaga T; Good AC; Rajamani R; Kish K; Tredup J; Klei HE; Gao Q; Mueller L; Colonno RJ; Grasela DM; Adams SP; Loy J; Levesque PC; Sun H; Shi H; Sun L; Warner W; Li D; Zhu J; Meanwell NA; McPhee F
    J Med Chem; 2014 Mar; 57(5):1730-52. PubMed ID: 24564672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.